Amgen Ventures

Amgen Ventures is the corporate venture capital arm of Amgen that makes direct investments in early through late-stage biotechnology companies. It focuses on discovering and developing human therapeutics across oncology, inflammation, bone health, nephrology, metabolic disorders, neuroscience, and cardiovascular diseases, including in oncology areas such as signal transduction, cell cycle, and apoptosis, and in supportive care like mucositis and cachexia. In nephrology it targets renal failure and hyperparathyroidism; in inflammation, rheumatoid arthritis, psoriasis, lupus, inflammatory bowel disease, multiple sclerosis, asthma, COPD, and osteoarthritis; in cardiovascular disease, acute coronary syndromes, dyslipidemia, and heart failure; and in metabolic disorders, diabetes and osteoporosis. It also covers neuroscience areas like pain, Alzheimer's, Parkinson's, sleep, cognition, and schizophrenia. The firm engages in early-stage research collaborations and technology, including antibody platforms, biomarkers, and computational tools. Headquartered in Thousand Oaks, with offices in San Francisco, Seattle, and Cambridge, it typically invests 2-3 million per transaction, up to 10 million per company, and seeks ownership under 15 percent. Founded 2004.